GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kukjeon Pharmaceutical Co Ltd (XKRX:307750) » Definitions » Beneish M-Score

Kukjeon Pharmaceutical Co (XKRX:307750) Beneish M-Score : -2.33 (As of Sep. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kukjeon Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Kukjeon Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

XKRX:307750' s Beneish M-Score Range Over the Past 10 Years
Min: -2.53   Med: -2.13   Max: 105.85
Current: -2.33

During the past 6 years, the highest Beneish M-Score of Kukjeon Pharmaceutical Co was 105.85. The lowest was -2.53. And the median was -2.13.


Kukjeon Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Kukjeon Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kukjeon Pharmaceutical Co Beneish M-Score Chart

Kukjeon Pharmaceutical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -2.18 -2.47 -1.92

Kukjeon Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.94 -2.08 -1.92 -2.47 -2.33

Competitive Comparison of Kukjeon Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - General subindustry, Kukjeon Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kukjeon Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kukjeon Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kukjeon Pharmaceutical Co's Beneish M-Score falls into.



Kukjeon Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kukjeon Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9138+0.528 * 1.1226+0.404 * 1.3968+0.892 * 1.17+0.115 * 0.4833
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.998+4.679 * -0.013781-0.327 * 1.0633
=-2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Total Receivables was ₩33,691 Mil.
Revenue was 33703.875 + 39310.132 + 30112.684 + 30145.348 = ₩133,272 Mil.
Gross Profit was 6050.718 + 6921.871 + 4764.377 + 6407.314 = ₩24,144 Mil.
Total Current Assets was ₩113,596 Mil.
Total Assets was ₩220,699 Mil.
Property, Plant and Equipment(Net PPE) was ₩89,110 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩4,607 Mil.
Selling, General, & Admin. Expense(SGA) was ₩5,867 Mil.
Total Current Liabilities was ₩94,748 Mil.
Long-Term Debt & Capital Lease Obligation was ₩24,814 Mil.
Net Income was 2326.187 + 1182.92 + 3130.539 + -1285.008 = ₩5,355 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was 2702.629 + 3642.797 + 1853.341 + 197.372 = ₩8,396 Mil.
Total Receivables was ₩31,509 Mil.
Revenue was 29860.942 + 31878.912 + 24799.435 + 27365.903 = ₩113,905 Mil.
Gross Profit was 6806.074 + 7298.954 + 5116.865 + 3944.645 = ₩23,167 Mil.
Total Current Assets was ₩123,117 Mil.
Total Assets was ₩209,662 Mil.
Property, Plant and Equipment(Net PPE) was ₩74,307 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩1,808 Mil.
Selling, General, & Admin. Expense(SGA) was ₩5,025 Mil.
Total Current Liabilities was ₩81,614 Mil.
Long-Term Debt & Capital Lease Obligation was ₩25,211 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(33690.601 / 133272.039) / (31509.397 / 113905.192)
=0.252796 / 0.276628
=0.9138

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(23166.538 / 113905.192) / (24144.28 / 133272.039)
=0.203384 / 0.181165
=1.1226

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (113595.904 + 89109.876) / 220699.046) / (1 - (123116.647 + 74306.944) / 209661.528)
=0.081529 / 0.05837
=1.3968

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=133272.039 / 113905.192
=1.17

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1808.422 / (1808.422 + 74306.944)) / (4606.624 / (4606.624 + 89109.876))
=0.023759 / 0.049155
=0.4833

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5867.448 / 133272.039) / (5025.075 / 113905.192)
=0.044026 / 0.044116
=0.998

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((24814.286 + 94748.483) / 220699.046) / ((25210.998 + 81613.625) / 209661.528)
=0.541746 / 0.50951
=1.0633

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(5354.638 - 0 - 8396.139) / 220699.046
=-0.013781

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kukjeon Pharmaceutical Co has a M-score of -2.33 suggests that the company is unlikely to be a manipulator.


Kukjeon Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Kukjeon Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Kukjeon Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
282, Hagui-Ro, Dongan-Gu, Gyeonggi-Do, Number 1516, Geumgang Penterium IT Tower, Anyang-Si, KOR
Kukjeon Pharmaceutical Co Ltd supplies raw materials to domestic and foreign pharmaceutical companies and electronic material companies. Some of the products of the company include Artemisia Princeps Folium 95% ethanol soft extract, Bilberry Fruit Dry Extract, Dexibuprofen, Megestrol Acetate, and Benfotiamine.

Kukjeon Pharmaceutical Co Headlines

No Headlines